Floatz logo

Idarubicin

Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22)

Bruno C. MedeirosSmall moleculePhase 2Dormant
BBB
76/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
64/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22) cohort.

Asset / SponsorPhaseRating
Daunomycin
National Cancer Institute (NCI)
Phase 3BBB
Cytarabine
Alice Mims
Phase 3BBB
Fludarabine
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 2BBB
Etoposide
Alice Mims
Phase 3BBB
Azacitidine
The First Affiliated Hospital of Soochow University
Phase 2BBB

View all 50 →

Same molecule, other indications

Idarubicin is also rated in:

acute promyelocytic leukemiaDormant
A
Indicative · Phase 4
81 / 100
View asset →
acute myeloid leukemia with 11q23 abnormalitiesDormant
BBB
Indicative · Phase 2
76 / 100
View asset →
adult acute lymphoblastic leukemiaActive
BBB
Indicative · Phase 4
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →